Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.39 |
| ▸ | CDK2 | P24941 | 6/20 | 0.39 |
| ▸ | CDK9 | P50750 | 6/20 | 0.39 |
| ▸ | CDK1 | P06493 | 6/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.39 |
| ▸ | CDK7 | P50613 | 5/20 | 0.39 |
| ▸ | CCNH | P51946 | 5/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740840 | 0.92 | PRKCQ (0.42) | SYKPRKCQCCNT1CCNA2CDK2 | |
| SCHEMBL3494409 | 0.91 | SYK (0.43) | SYKPRKCQCCNT1CCNA2CDK2 | |
| SCHEMBL3496736 | 0.87 | PRKCQ (0.55) | SYKPRKCQCCNT1CCNA2CDK2 | |
| SCHEMBL3494922 | 0.84 | SYK (0.51) | SYKPRKCQCDK1LRRK2 | |
| SCHEMBL3493908 | 0.83 | CSNK2A2 (0.49) | SYKPRKCQCCNT1CCNA2CDK2 | |
| SCHEMBL3495606 | 0.82 | PRKCQ (0.61) | SYKPRKCQCCNT1CCNA2CDK2 | |
| SCHEMBL1740742 | 0.82 | SYK (0.42) | SYKPRKCQCCNT1CCNA2CDK2 | |
| SCHEMBL3496786 | 0.80 | PRKCQ (0.49) | SYKPRKCQCCNT1CCNA2CDK2 | |
| SCHEMBL3496008 | 0.80 | PRKCQ (0.54) | SYKPRKCQCCNT1CDK2CDK9 | |
| SCHEMBL3496441 | 0.79 | PRKCQ (0.39) | SYKPRKCQCCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | SYK 460/4885PRKCQ 3/4885CCNT1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.